Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy

Sadako Nishimura, Hiroshi Tsuda, Fumio Kataoka, Tokuzo Arao, Hiroyuki Nomura, Tatsuyuki Chiyoda, Nobuyuki Susumu, Kazuto Nishio, Daisuke Aoki

研究成果: Article

19 引用 (Scopus)

抄録

The aim of this study was to examine the relation between cofilin 1 expression and progression-free survival in advanced epithelial ovarian cancer. We performed quantitative reverse transcriptase polymerase chain reaction and immunohistochemical analysis in 78 patients with advanced epithelial ovarian cancer (excluding those with mucinous and clear-cell types). All patients received the standard therapy, including staging laparotomy and adjuvant chemotherapy consisting of carboplatin and paclitaxel. Of 78 samples, RNA from 62 samples was available for reverse transcriptase polymerase chain reaction analysis. We defined cofilin 1 high expression as relative gene expression equal to or higher than the median and low expression as gene expression lower than median. The progression-free survival was longer in cofilin 1 low-expression cases than in high-expression cases (P = .039). Multivariate analysis demonstrated that stage and cofilin 1 expression were significant predictors of progression-free survival. Of the 78 samples, 54 were appropriate for immunohistochemical study. In 35 of those 54 cases, cofilin 1 protein expression was detected. The progression-free survival was longer in cofilin 1 protein-negative cases than in protein-positive cases (P = .042). Expression of cofilin 1 may predict the progression-free survival of patients with advanced epithelial ovarian cancer receiving standard therapy.

元の言語English
ページ(範囲)516-521
ページ数6
ジャーナルHuman Pathology
42
発行部数4
DOI
出版物ステータスPublished - 2011 4

Fingerprint

Cofilin 1
Disease-Free Survival
Actin Depolymerizing Factors
Reverse Transcriptase Polymerase Chain Reaction
Therapeutics
Gene Expression
Carboplatin
Adjuvant Chemotherapy
Paclitaxel
Ovarian epithelial cancer
Laparotomy
Multivariate Analysis
RNA

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

これを引用

Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy. / Nishimura, Sadako; Tsuda, Hiroshi; Kataoka, Fumio; Arao, Tokuzo; Nomura, Hiroyuki; Chiyoda, Tatsuyuki; Susumu, Nobuyuki; Nishio, Kazuto; Aoki, Daisuke.

:: Human Pathology, 巻 42, 番号 4, 04.2011, p. 516-521.

研究成果: Article

Nishimura, Sadako ; Tsuda, Hiroshi ; Kataoka, Fumio ; Arao, Tokuzo ; Nomura, Hiroyuki ; Chiyoda, Tatsuyuki ; Susumu, Nobuyuki ; Nishio, Kazuto ; Aoki, Daisuke. / Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy. :: Human Pathology. 2011 ; 巻 42, 番号 4. pp. 516-521.
@article{192c25a70ce54f638875975b1df6ff85,
title = "Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy",
abstract = "The aim of this study was to examine the relation between cofilin 1 expression and progression-free survival in advanced epithelial ovarian cancer. We performed quantitative reverse transcriptase polymerase chain reaction and immunohistochemical analysis in 78 patients with advanced epithelial ovarian cancer (excluding those with mucinous and clear-cell types). All patients received the standard therapy, including staging laparotomy and adjuvant chemotherapy consisting of carboplatin and paclitaxel. Of 78 samples, RNA from 62 samples was available for reverse transcriptase polymerase chain reaction analysis. We defined cofilin 1 high expression as relative gene expression equal to or higher than the median and low expression as gene expression lower than median. The progression-free survival was longer in cofilin 1 low-expression cases than in high-expression cases (P = .039). Multivariate analysis demonstrated that stage and cofilin 1 expression were significant predictors of progression-free survival. Of the 78 samples, 54 were appropriate for immunohistochemical study. In 35 of those 54 cases, cofilin 1 protein expression was detected. The progression-free survival was longer in cofilin 1 protein-negative cases than in protein-positive cases (P = .042). Expression of cofilin 1 may predict the progression-free survival of patients with advanced epithelial ovarian cancer receiving standard therapy.",
keywords = "Cofilin 1, Ovarian cancer, Prognostic biomarker",
author = "Sadako Nishimura and Hiroshi Tsuda and Fumio Kataoka and Tokuzo Arao and Hiroyuki Nomura and Tatsuyuki Chiyoda and Nobuyuki Susumu and Kazuto Nishio and Daisuke Aoki",
year = "2011",
month = "4",
doi = "10.1016/j.humpath.2010.07.019",
language = "English",
volume = "42",
pages = "516--521",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy

AU - Nishimura, Sadako

AU - Tsuda, Hiroshi

AU - Kataoka, Fumio

AU - Arao, Tokuzo

AU - Nomura, Hiroyuki

AU - Chiyoda, Tatsuyuki

AU - Susumu, Nobuyuki

AU - Nishio, Kazuto

AU - Aoki, Daisuke

PY - 2011/4

Y1 - 2011/4

N2 - The aim of this study was to examine the relation between cofilin 1 expression and progression-free survival in advanced epithelial ovarian cancer. We performed quantitative reverse transcriptase polymerase chain reaction and immunohistochemical analysis in 78 patients with advanced epithelial ovarian cancer (excluding those with mucinous and clear-cell types). All patients received the standard therapy, including staging laparotomy and adjuvant chemotherapy consisting of carboplatin and paclitaxel. Of 78 samples, RNA from 62 samples was available for reverse transcriptase polymerase chain reaction analysis. We defined cofilin 1 high expression as relative gene expression equal to or higher than the median and low expression as gene expression lower than median. The progression-free survival was longer in cofilin 1 low-expression cases than in high-expression cases (P = .039). Multivariate analysis demonstrated that stage and cofilin 1 expression were significant predictors of progression-free survival. Of the 78 samples, 54 were appropriate for immunohistochemical study. In 35 of those 54 cases, cofilin 1 protein expression was detected. The progression-free survival was longer in cofilin 1 protein-negative cases than in protein-positive cases (P = .042). Expression of cofilin 1 may predict the progression-free survival of patients with advanced epithelial ovarian cancer receiving standard therapy.

AB - The aim of this study was to examine the relation between cofilin 1 expression and progression-free survival in advanced epithelial ovarian cancer. We performed quantitative reverse transcriptase polymerase chain reaction and immunohistochemical analysis in 78 patients with advanced epithelial ovarian cancer (excluding those with mucinous and clear-cell types). All patients received the standard therapy, including staging laparotomy and adjuvant chemotherapy consisting of carboplatin and paclitaxel. Of 78 samples, RNA from 62 samples was available for reverse transcriptase polymerase chain reaction analysis. We defined cofilin 1 high expression as relative gene expression equal to or higher than the median and low expression as gene expression lower than median. The progression-free survival was longer in cofilin 1 low-expression cases than in high-expression cases (P = .039). Multivariate analysis demonstrated that stage and cofilin 1 expression were significant predictors of progression-free survival. Of the 78 samples, 54 were appropriate for immunohistochemical study. In 35 of those 54 cases, cofilin 1 protein expression was detected. The progression-free survival was longer in cofilin 1 protein-negative cases than in protein-positive cases (P = .042). Expression of cofilin 1 may predict the progression-free survival of patients with advanced epithelial ovarian cancer receiving standard therapy.

KW - Cofilin 1

KW - Ovarian cancer

KW - Prognostic biomarker

UR - http://www.scopus.com/inward/record.url?scp=79952988205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952988205&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2010.07.019

DO - 10.1016/j.humpath.2010.07.019

M3 - Article

C2 - 21237490

AN - SCOPUS:79952988205

VL - 42

SP - 516

EP - 521

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 4

ER -